JPRN-UMIN000003344尚未招募未知
Induction of the remission by use of infliximab in RA - Induction of the remission by use of infliximab in RA
Division of Rheumatology, Department of Internal Medicine, Kanazawa University Hospital0 个研究点目标入组 20 人开始时间: 2010年3月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who correspond to the contraindication for use of infliximab and MTX 2) Patients who are more than 70 years old at enrollment 3) Patients who have contracted RA for more than 10 years 4) Patients who are treated with more than 10mg of predonisolone 5) Other patients whom the investigator considers to be unsuitable for the study
研究者
相似试验
已完成
3 期
Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)Extrathoracic SarcoidosisNCT03704610Assistance Publique - Hôpitaux de Paris31
进行中（未招募）
1 期
BackToBasic: The effect of Infliximab in patients with chronic low back pain and vertebral oedema on MRI scan.A randomized, double blind, placebo-controlled, multicenter trialon-specific chronic low back pain of more than 6 months duration. We will only investigate those who have vertebral end-plate chanages(Modic changes) on MRI.MedDRA version: 20.0Level: LLTClassification code 10008837Term: Chronic back painSystem Organ Class: 100000004859EUCTR2017-004861-29-NOFOU, Nevroklinikken, Oslo University Hospital -Ullevål126
进行中（未招募）
不适用
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-DKSchering-Plough Research Institute, a Division of Schering Corporation150
进行中（未招募）
1 期
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-BESchering-Plough Research Institute, a Division of Schering Corporation150
进行中（未招募）
1 期
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1 Level: LLT Classification code 10058338 Term: SpondylarthritisEUCTR2008-000982-51-FRSchering-Plough Research Institute, a Division of Schering Corporation150